Trial intelligence / Profile preview

ATLAS-A/B: Fitusiran in Hemophilia A or B Without Inhibitors

NCT03417245Phase 3Completed

Sponsor
Sanofi
Start
Mar 2018
Primary completion
Jan 2021
Modality
Conjugated siRNA, Chemically Modified siRNA
Countries
19
01

Overview

A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Mar 2018; status: completed.

02

Drugs

fitusiran
03

Conditions

hemophilia Ahemophilia B (HB)

Beyond the preview

Go deeper on NCT03417245.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03417245.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call